For ELISA: Use at a concentration of 3 - 5μg/ml. Using plates coated with 100 μl/well of the capture antibody (monoclonal anti-human IGFBP3) at 4 μg/ml, in combination with 100 μl/well of a detection antibody (biotinylated IGFBP3) at 400 ng/ml, an ELISA with a range from 125 to 8000 pg/ml can be obtained for sample volumes of 100 ml. For IHC-P: Use at a concentration of 8 - 25 μg/ml on paraffin-embedded tissue sections (5 to 15 μm thick). For WB: Use at a concentration of 1 - 2 μg/ml. Detects a band of approximately 41 kDa. Optimal dilutions/concentrations should be determined by the researcher.
When used with a biotinylated anti human IGFBP3 detection antibody in sandwich ELISAs, this antibody shows less than 0.001 % cross-reactivity with recombinant human IGFI, IGFIR, IGFII, IGFBP1, IGFBP2, IGFBP4, IGFBP5, and IGFBP6.
PBS, no preservatives added
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
0.5 mg/ml (Please refer to the vial label for the specific concentration.)
Recombinant full length protein (Human).
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Insulin Like Growth Factor Binding Protein 3,Bp-53,Ibp3,Igfbp3
Insulin like growth factor binding protein 3 (IGFBP3) is a member of the superfamily of insulin like growth factor (IGF) binding proteins which include six high affinity IGF binding proteins (IGFBP) and at least four lowaffinity binding proteins referred to as IGFBP related proteins (IGFBPrP). The IGFBP members are cysteine rich proteins with conserved cysteine residues clustered in the amino terminal and the carboxy terminal regions of the molecule. The cDNA sequence encoding the mature human IGFBP3 is fused to the signal peptide of CD33. The 265 amino acid residue recombinant mature human IGFBP3 has a calculated molecular mass of approximately 29 kDa. Due to glycosylation, the recombinant protein migrates as 41 kDa in SDS-PAGE. Human IGFBP3 is the major IGF binding protein in plasma where it exists in a ternary complex with IGFI or IGFII and an acid labile subunit. IGFBPs hold a central position in IGF ligand-receptor interactions through influences on both the bioavailability and distribution of IGFs in the extracellular environment. Insulin like growth factor binding protein 3 (IGFBP3) can modulate the mitogenic and metabolic effects of the insulin-like growth factors (IGFs). Insulin like growth factor binding protein 3 (IGFBP3) is expressed in multiple tissues. The highest expression level is found in the non-paranchymal cells of the liver. The expression levels are higher during extrauterine life and peak during puberty. Insulin like growth factors (IGFs) and IGF binding proteins (IGFBPs) play important roles in cell growth and differentiation. IGFBP3 is one of the factors in serum that is responsible for high-serum-induced apoptosis in PC-3 cells, a prostate cancer cell line. IGFBP3 is important in controlling glucose homeostasis with increased urinary levels in type I diabetes with persistent microalbuminuria.